Cancer risks in Jewish male BRCA1 and BRCA2 mutation carriers

Yael Laitman, Lital Keinan Boker, Irena Liphsitz, Daphna Weissglas-Volkov, Shira Litz-Philipsborn, Hagit Schayek, Eitan Friedman

Research output: Contribution to journalArticlepeer-review


Cancer risks and tumor types in male BRCA1 and BRCA2 mutation carriers are still unsettled. Cancer risks in men who were found to harbor a BRCA1 (n = 150) or a BRCA2 (n = 88) mutation or both (n = 2) were assessed by cross referencing with data on cancer occurrence in the Israeli National Cancer Registry. Incidence rates in mutation carriers were compared with men who were counseled, genotyped, and found not to harbor the familial mutation (true negative n = 122), and with standardized incidence rates (SIRs). Of 210 cancer-free individuals at initial counseling, 11 cancers were diagnosed after a mean follow-up of 5.06 ± 4.1 years (1064 person/years) compared with 1/122 in a BRCA true-negative man. The SIR for all BRCA1/2 mutation carriers compared with the rates in the general population were elevated for pancreatic cancer [2.97 (95 % CI 1.83–4.29)] and breast cancer [16.44 (95 % CI 9.65–26.24)]. For prostate cancer these rates were 0.59 (95 % CI 0.4–0.84). Jewish BRCA1/2 mutation carriers are at an increased risk for breast and pancreatic, but not prostate cancer. These cancer risks and the consequent recommendations, if validated, should be transmitted to carriers at test result disclosure.

Original languageEnglish
Pages (from-to)631-635
Number of pages5
JournalBreast Cancer Research and Treatment
Issue number3
StatePublished - 1 Apr 2015

Bibliographical note

Publisher Copyright:
© 2015, Springer Science+Business Media New York.


  • BRCA germline mutations
  • Cancer risk
  • Male breast cancer
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Cancer risks in Jewish male BRCA1 and BRCA2 mutation carriers'. Together they form a unique fingerprint.

Cite this